aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19
May 12, 2020 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Research Collaboration with Boston Children’s Hospital
October 22, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Participate in September Conferences
September 18, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
August 14, 2019 08:00 ET
|
aTyr Pharma, Inc.
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August...
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
August 07, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
August 06, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the...
aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
July 10, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
July 01, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
May 13, 2019 16:05 ET
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host...